6 results about "Succinylation" patented technology

The application provides a high-temperature-resistant and gastric acid-resistant probiotic preparation and a preparation method thereof, and the preparation comprises a probiotic core layer and a shell layer covering the same, and the shell layer comprises succinyl-modified food leaf protein assisted by ultrasonic pretreatment, peach gum polysaccharide and soybean lecithin. The application constructs a single-layer protection system with excellent responsiveness by performing specific functional modification on the food leaf protein and synergizing the food leaf protein with the peach gum polysaccharide and the soybean lecithin. The preparation can significantly improve the survival rate of probiotics during processing, storage and simulated gastrointestinal digestion, and especially realizes excellent gastric acid resistance and intestinal targeting release performance, and the process is simple and suitable for embedding and protecting various probiotics.

This invention relates to the field of biomedical technology, disclosing succinylated modified RAD51 protein, formulations for promoting RAD51 succinylation, and their applications. The method includes: seeding and culturing cells and transfecting them with a tagged RAD51 expression plasmid; adding sodium succinate and an HDAC11 inhibitor to the culture medium for continued culturing to allow intracellular modification accumulation; collecting the supernatant after cell lysis and incubating it with magnetic beads containing anti-tag antibodies under cold conditions; washing and eluting with an elution buffer containing the tagged peptide; performing immunoblotting analysis using antibodies that specifically recognize the modified site to obtain the succinylated modified RAD51 protein. This invention, by adding sodium succinate and an HDAC11 inhibitor, provides a substrate and blocks the demodification pathway. Combined with magnetic bead purification and competitive elution, it avoids disrupting the protein conformation, obtaining a protein that retains its native activity and has a high level of modification, providing a core component for screening targeted drugs.

The application belongs to the field of drug delivery nanotechnology, and provides a method for preparing cubic lipid nanoparticles encapsulating small interfering ribonucleic acid and application thereof. The application adopts a trinity design of ion complex pre-assembly of succinylated glycerol monooleate and cationic lipids, space stabilization of poloxamer 407, and rapid particle formation by microfluidics, realizes stable construction of internal nanostructure of inverse bicontinuous cubic phase, encapsulation of small interfering ribonucleic acid in water channel network with high drug loading, long-term stability of colloids under physiological ion strength conditions, and excellent batch consistency, solves the technical contradictions of existing lipid nanometer delivery systems, such as difficulty in giving consideration to low polydispersion and batch consistency, mutual restraint of cationic complex strength and colloidal stability, and difficulty in synergistic optimization of high drug loading and stability of cubic phase structure under high solid content microfluidic conditions, and has wide application value in gene therapy and nucleic acid drug delivery.

This invention belongs to the field of biomedical material preparation technology, specifically disclosing a method for moist heat sterilization of recombinant collagen fillers. The method includes: preparing a protective solution from modified trehalose and proline, then mixing it with homogenized recombinant collagen hydrogel, followed by staged temperature-controlled moist heat sterilization. This invention modifies trehalose by succinylation, introducing carboxyl groups onto the trehalose molecule, enabling electrostatic interactions with cationic groups on the surface of collagen molecules. During moist heat sterilization, free proline guides the heat-denatured collagen to refold into its natural triple helix structure. The preheating stage allows the collagen to gradually adapt to the thermal environment, avoiding conformational shock damage caused by sudden temperature increases, effectively shortening the high-temperature sterilization time, and significantly reducing the cumulative heat effect on molecular structure. This method is simple to operate, requires no special equipment, and has good prospects for industrial application.

The present application belongs to the technical field of modified yeast protein, and particularly relates to a double modified yeast protein purification product, a heat-induced gel and preparation and application thereof. The solubility of the double modified yeast protein purification product is greater than 15.00%, the turbidity is less than 1.70, the particle size is less than 1500.00 nm, the Zeta potential is less than -47.00 mV, and the succinylated degree is greater than 20.00%. The double modified yeast protein purification product is obtained by mixing yeast protein powder suspension with a pH of 7.0-11.0 and succinic anhydride at a dry matter mass ratio of 0.1:1-0.5:1, then performing succinylation reaction, ultrasonic treatment under a ultrasonic power of 200-600 W, and dialysis. The present application promotes specific conformational changes and interactions of modified yeast protein molecules in the double modified yeast protein purification product by controlled heat-induced technology, and a double modified yeast protein heat-induced gel product with good gel performance, transparency, water holding capacity and gel strength is prepared.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.